Skip to main content

Treatment of Prostate Cancer

Gene discovery revolutionizes the detection and treatment of prostate cancer


Genetic studies reveal how PSA variations affect prostate cancer detection and outcomes, paving the way for personalized diagnostic tools and care.

Prostate cancer is the second most common cancer affecting men globally, with diagnostic methods and risk assessment remaining a challenge despite decades of research. For years, the prostate-specific antigen (PSA) blood test has been a cornerstone in detecting prostate cancer

However, while PSA testing has been shown to reduce prostate cancer-related deaths, it also leads to over-diagnosis. This calls for a shift toward more individualized and informed approaches to screening, especially for younger men.

PSA’s biological role goes beyond its use as a diagnostic marker. It plays a critical role in liquefying semen and tumor progression by interacting with growth factors and proteins in the extracellular matrix. This activity promotes cancer cell migration, bone metastasis, and blood vessel formation in tumors.

Despite its clinical utility, PSA’s ability to distinguish between aggressive and indolent cancers remains limited. Recent advancements in genetics offer insights into this limitation and present opportunities for improved diagnostic methods.

Genome-wide association studies (GWAS) have identified more than 450 single nucleotide polymorphisms (SNPs) linked to prostate cancer risk. These SNPs account for approximately 42.6% of familial prostate cancer risk in individuals of European ancestry. Among them, a specific SNP in the KLK3 gene—which encodes PSA—has drawn significant attention.

Known as rs17632542, this SNP causes an amino acid substitution from isoleucine to threonine (Ile163Thr) in PSA. This genetic variation is associated with reduced prostate cancer risk, yet its precise role in the disease has remained unclear.

Recent research, published in the journal, Nature Communications, sheds light on how this SNP influences PSA’s biochemical activity and its implications for cancer progression. Laboratory and animal studies reveal that the Ile163Thr variant alters PSA’s proteolytic activity, impacting the tumor microenvironment.

This variant is linked to smaller primary tumors but higher metastatic potential, particularly to the bones, where it triggers pronounced bone loss. These findings highlight the dual nature of this genetic variation: while it reduces overall cancer risk, it paradoxically increases the likelihood of aggressive disease.

The SNP’s impact extends to PSA levels in the blood. Carriers of this variant typically exhibit lower total PSA and a higher free-to-total PSA ratio. This could lead to delayed prostate cancer diagnosis, as lower PSA levels might not trigger early biopsy recommendations. Consequently, some aggressive cancers may go undetected until later stages, resulting in worse outcomes.

“Through comprehensive lab and mice tests, we found that this SNP, although associated with reduced prostate cancer risk, is also associated with an aggressive type of this cancer,” said Dr. Srinivasan, one of the study’s lead researchers. She emphasized that the findings help explain anomalies in current diagnostic practices and underscore the need for improved screening tools.

Despite its limitations, the PSA test remains a vital diagnostic tool. However, it cannot differentiate between aggressive and non-aggressive cancers.

This limitation leads to over-diagnosis, over-treatment, and unnecessary biopsies, which impact patients’ quality of life and increase healthcare costs. At the same time, low PSA levels associated with aggressive cancers may result in delayed diagnosis and higher mortality.

Professor Jyotsna Batra, who spearheaded the study, highlighted the potential for personalized medicine to address these challenges. “Findings from this study may lead to developing a novel and simple point-of-care device,” she said.

Such a device could identify patients with genetic variations linked to aggressive prostate cancer, even when PSA levels are low. This would enable general practitioners to provide tailored diagnostic assessments and guide clinical decisions more effectively.

Collaborative efforts by researchers have advanced understanding of how genetic variations influence prostate cancer outcomes. The research team, led by Professor Batra and QUT Distinguished Professor Emeritus Judith Clements, included experts from bioinformatics, biomedical sciences, and clinical practice.

Their findings could revolutionize prognostic prediction by distinguishing more aggressive cancers and identifying high-risk groups who need early intervention.

This breakthrough research highlights the interplay between genetics and diagnostic markers like PSA. By identifying the functional implications of the rs17632542 SNP, scientists are paving the way for more accurate and individualized approaches to prostate cancer care. The study’s findings emphasize the importance of integrating genetic data into routine screening and treatment protocols.

As researchers continue to unravel the complexities of prostate cancer genetics, the goal of personalized medicine comes closer to reality. With tools informed by genetic variations, clinicians could one day offer more precise and effective care, reducing the burden of over-diagnosis while improving outcomes for those with aggressive disease.

This innovative approach aligns with an era of personalized treatment, where genetic insights transform how diseases like prostate cancer are managed.

radiation therapy, chemotherapy, hormone therapy, immunotherapy, targeted therapy, active surveillance, radical prostatectomy, robotic-assisted surgery, external beam radiation, brachytherapy, androgen deprivation therapy, PSA monitoring, clinical trials, bone-targeted therapy, cryotherapy, high-intensity focused ultrasound (HIFU), genomic testing, combination therapy, metastasis management

#ProstateCancer #CancerTreatment #RadiationTherapy #Chemotherapy #HormoneTherapy #Immunotherapy #TargetedTherapy #ActiveSurveillance #RadicalProstatectomy #RoboticSurgery #ExternalBeamRadiation #Brachytherapy #AndrogenDeprivation #PSAMonitoring #ClinicalTrials #BoneHealth #Cryotherapy #HIFU #GenomicTesting #MetastaticCancer

Comments

Post a Comment

Popular posts from this blog

Genetics role in ovarian cancer

The Medical Minute: Genetics play big role in ovarian cancer In 2024, about 19,680 women in the United States will receive a new diagnosis of ovarian cancer and 12,740 women will die from the disease, said Dr. Shaina Bruce , a gynecologic oncologist at Penn State Cancer Institute . The median age of all patients who develop ovarian cancer is 63. Historically, women at increased risk for ovarian cancer are recommended to have their fallopian tubes and ovaries removed when they have completed having children. Taking that step to protect themselves comes at a heavy price ― surgical menopause. But Bruce said medical science is catching up with ovarian cancer. Studies could lead to new methods for preventative care and the surgery needed to lower risk may be easier than it once was. Below, during Gynecologic Cancer Awareness Month, Bruce discusses the disease and why acting to reduce your risk is worth it. What’s the connection between heredity and ovarian cancer? About 25% of all cases of ...
Post a Comment
Read more

Migration in Population Genetics

  Migration in Population Genetics Migration in population genetics refers to the movement of individuals-and therefore their genes -between different populations of the same species. This gene flow alters allele frequencies, increasing genetic diversity within populations while reducing genetic differences between them. Migration can counteract the effects of genetic drift and inbreeding , introduce new alleles , and influence evolutionary processes such as adaptation and natural selection. The rate, direction, and scale of migration play a crucial role in shaping population structure, evolutionary potential, and long-term species survival, especially in fragmented habitats or changing environments. Migration, Population Genetics, Gene Flow, Allele Frequency, Genetic Diversity, Evolution, Genetic Variation, Population Structure, Adaptation, Biodiversity #PopulationGenetics #Migration #GeneFlow #GeneticDiversity #EvolutionaryBiology #AlleleFrequency #NaturalSelection #GeneticD...
Post a Comment
Read more

Chromosomal Abnormalities

  Chromosomal Abnormalities Chromosome abnormalities refer to structural or numerical changes in chromosomes that can disrupt normal genetic function, leading to developmental disorders, congenital abnormalities, and various genetic diseases. These abnormalities may arise from errors in cell division, such as nondisjunction or chromosomal breakage, resulting in conditions like Down syndrome , Turner syndrome, Klinefelter syndrome , and various deletion or duplication syndromes. Understanding chromosome abnormalities is essential for genetic counseling, prenatal diagnosis, disease risk assessment, and research in cytogenetics and molecular genetics. Chromosome abnormalities, chromosomal disorders, chromosomal mutations, aneuploidy, structural chromosome abnormalities, nondisjunction, deletion syndrome, duplication syndrome , translocation, inversion, cytogenetics, karyotyping, prenatal diagnosis , genetic testing, genomic instability, Down syndrome, Turner syndrome, Klinefelter syn...
Post a Comment
Read more